Steve Moores, from Mawdesley, Lancashire, has completed his series of extraordinary fundraising challenges for Parkinson’s UK ...

Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

Dr. Gina Boerger, PT, DPT, of Fort Loramie, has authored a resource book for people with Parkinson’s disease. Dr. Boerger has ...

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Managing patients with Parkinson's disease should be viewed as part of a hospital CMO's responsibility for patient safety and ...

Discover how tremor monitoring in mice offers valuable insights into neurological disorders, motor function, and disease progression.

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

Parkinson’s disease is a challenging condition that affects millions of people around the world. It is known for causing ...